Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Hinge Health (HNGE) Amortization of Deferred Charges (2024 - 2025)

Hinge Health (HNGE) has disclosed Amortization of Deferred Charges for 2 consecutive years, with $14.2 million as the latest value for Q4 2025.

Quarterly Amortization of Deferred Charges rose 57.56% to $14.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $43.3 million through Dec 2025, changed N/A year-over-year, with the annual reading at $46.7 million for FY2025, 56.0% up from the prior year.
Amortization of Deferred Charges hit $14.2 million in Q4 2025 for Hinge Health, up from $12.6 million in the prior quarter.
In the past five years, Amortization of Deferred Charges ranged from a high of $14.2 million in Q4 2025 to a low of $7.5 million in Q3 2024.